ChabioTech Completes Phase 1 Clinical Trial of Cancer Immunotherapy 'CBT101'

[Asia Economy Reporter Chunhee Lee] Cha Biotech has confirmed the safety and tolerability of the solid tumor immunotherapy 'CBT101' through its Phase 1 clinical trial.

Cha Biotech announced the topline data of the Phase 1 clinical trial of CBT101 on the 3rd. CBT101 is an immune cell therapy manufactured by extracting NK cells, which play a crucial role in innate immunity, from the patient's own blood and expanding them ex vivo. By applying Cha Biotech's cell culture technology, the proliferation capacity of NK cells was increased approximately 2000-fold, and the NK cell activity, which was previously around 5-10%, was enhanced up to 90%, significantly improving the anticancer effect.

This clinical trial was conducted to confirm the safety and tolerability of intravenous administration of CBT101 in solid tumor patients who had undergone cancer resection surgery and completed adjuvant therapy. The trial involved a total of six patients; among them, three experienced adverse drug reactions, but these were mild and found to have no causal relationship with CBT101.

Cha Biotech plans to prepare the final clinical trial report and submit it to the Ministry of Food and Drug Safety by the 29th. Based on the Phase 1 results, the company intends to conduct a Phase 2 clinical trial targeting recurrent glioblastoma patients in Korea and to pursue clinical trials in the United States using domestic clinical data.

Osanghoon Cha, CEO of Cha Biotech, stated, “We will strive to expedite commercialization through rapid clinical trials to provide hope to patients suffering from a lack of effective treatments.” He added, “Upon completion of the clinical trials, we plan to collaborate with our U.S. subsidiary, Matica Biotechnology, which is engaged in cell and gene therapy (CGT) contract development and manufacturing organization (CDMO) business, to enter the global market.”

This content was produced with the assistance of AI translation services.